Advocate

Country: European Union

Language: Spanish

Source: EMA (European Medicines Agency)

Buy It Now

Active ingredient:

imidacloprid, moxidectina

Available from:

Bayer Animal Health GmbH

ATC code:

QP54AB52

INN (International Name):

imidacloprid, moxidectin

Therapeutic group:

Dogs; Cats; Ferrets

Therapeutic area:

Productos antiparasitarios, insecticidas y repelentes

Therapeutic indications:

DogsFor perros que sufren, o corren el riesgo de, mezclado infecciones parasitarias:el tratamiento y la prevención de la infestación de pulgas (Ctenocephalides felis),el tratamiento de picaduras de piojos (Trichodectes canis),el tratamiento de la infestación de ácaros del oído (Otodectes cynotis), la sarna sarcóptica (causada por el Sarcoptes scabiei var. canis), infección (causada por Demodex canis),la prevención de la enfermedad del gusano del corazón (L3 y L4 larvas de Dirofilaria immitis),el tratamiento de la circulación de microfilarias (Dirofilaria immitis),el tratamiento de la cutánea dirofilariosis (etapas adultas de Dirofilaria repens)la prevención de la cutánea dirofilariosis (L3 larvas de Dirofilaria repens),la reducción de la circulación de microfilarias (Dirofilaria repens),la prevención de la angiostrongylosis (larvas L4 inmaduros y adultos de Angiostrongylus vasorum),el tratamiento de Angiostrongylus vasorum y Crenosoma vulpis,la prevención de la spirocercosis (Spirocerca lupi),el tratamiento de Eucoleus (syn. Capillaria) boehmi (adultos),el tratamiento del gusano del ojo Thelazia callipaeda (adultos),el tratamiento de las infecciones por nematodos gastrointestinales (larvas L4, inmaduros y adultos de Toxocara canis, Ancylostoma caninum y Uncinaria stenocephala, los adultos de Toxascaris leonina y Trichuris vulpis). El producto puede usarse como parte de una estrategia de tratamiento para la dermatitis alérgica a las pulgas (FAD). CatsFor los gatos que sufren, o corren el riesgo de, mezclado infecciones parasitarias:el tratamiento y la prevención de la infestación de pulgas (Ctenocephalides felis),el tratamiento de la infestación de ácaros del oído (Otodectes cynotis),el tratamiento de notoedric de la sarna (Notoedres cati),el tratamiento de la estrongilosis pulmonar Eucoleus aerophilus (syn. Capillaria aerophila) (adultos),la prevención de la estrongilosis pulmonar de la enfermedad (L3/L4 larvas de Aelurostrongylus abstrusus),el tratamiento de la estrongilosis pulmonar Aelurostrongylus abstrusus (adultos),el tratamiento del gusano del ojo Thelazia callipaeda (adultos),la prevención de la enfermedad del gusano del corazón (L3 y L4 larvas de Dirofilaria immitis),el tratamiento de las infecciones por nematodos gastrointestinales (larvas L4, inmaduros y adultos de Toxocara cati y Ancylostoma tubaeforme). El producto puede usarse como parte de una estrategia de tratamiento para la dermatitis alérgica a las pulgas (FAD). FerretsFor hurones que sufren, o corren el riesgo de, mezclado infecciones parasitarias:el tratamiento y la prevención de la infestación de pulgas (Ctenocephalides felis),la prevención de la enfermedad del gusano del corazón (L3 y L4 larvas de Dirofilaria immitis).

Product summary:

Revision: 23

Authorization status:

Autorizado

Authorization date:

2003-04-02

Patient Information leaflet

                                OFFICIAL ADDRESS
Domenico Scarlattilaan 6
●
1083 HS Amsterdam
●
The Netherlands
An agency of the European Union
ADDRESS FOR VISITS AND DELIVERIES
Refer to www.ema.europa.eu/how-to-find-us
SEND US A QUESTION
Go to
www.ema.europa.eu/contact
TELEPHONE
+31 (0)88 781
6000
© European Medicines Agency,
2023. Reproduction is authorised provided the source is acknowledged.
La información actualizada sobre este medicamento veterinario está
disponible en el sitio web de
información sobre medicamentos veterinarios.
                                
                                Read the complete document
                                
                            

Summary of Product characteristics

                                OFFICIAL ADDRESS
Domenico Scarlattilaan 6
●
1083 HS Amsterdam
●
The Netherlands
An agency of the European Union
ADDRESS FOR VISITS AND DELIVERIES
Refer to www.ema.europa.eu/how-to-find-us
SEND US A QUESTION
Go to
www.ema.europa.eu/contact
TELEPHONE
+31 (0)88 781
6000
© European Medicines Agency,
2023. Reproduction is authorised provided the source is acknowledged.
La información actualizada sobre este medicamento veterinario está
disponible en el sitio web de
información sobre medicamentos veterinarios.
                                
                                Read the complete document
                                
                            

Documents in other languages

Patient Information leaflet Patient Information leaflet Bulgarian 31-01-2024
Summary of Product characteristics Summary of Product characteristics Bulgarian 31-01-2024
Public Assessment Report Public Assessment Report Bulgarian 29-01-2024
Patient Information leaflet Patient Information leaflet Czech 31-01-2024
Public Assessment Report Public Assessment Report Czech 29-01-2024
Patient Information leaflet Patient Information leaflet Danish 31-01-2024
Public Assessment Report Public Assessment Report Danish 29-01-2024
Patient Information leaflet Patient Information leaflet German 31-01-2024
Public Assessment Report Public Assessment Report German 29-01-2024
Patient Information leaflet Patient Information leaflet Estonian 31-01-2024
Public Assessment Report Public Assessment Report Estonian 29-01-2024
Patient Information leaflet Patient Information leaflet Greek 31-01-2024
Public Assessment Report Public Assessment Report Greek 29-01-2024
Patient Information leaflet Patient Information leaflet English 31-01-2024
Public Assessment Report Public Assessment Report English 29-01-2024
Patient Information leaflet Patient Information leaflet French 31-01-2024
Public Assessment Report Public Assessment Report French 29-01-2024
Patient Information leaflet Patient Information leaflet Italian 31-01-2024
Public Assessment Report Public Assessment Report Italian 29-01-2024
Patient Information leaflet Patient Information leaflet Latvian 31-01-2024
Public Assessment Report Public Assessment Report Latvian 29-01-2024
Patient Information leaflet Patient Information leaflet Lithuanian 31-01-2024
Summary of Product characteristics Summary of Product characteristics Lithuanian 31-01-2024
Public Assessment Report Public Assessment Report Lithuanian 29-01-2024
Patient Information leaflet Patient Information leaflet Hungarian 31-01-2024
Summary of Product characteristics Summary of Product characteristics Hungarian 31-01-2024
Public Assessment Report Public Assessment Report Hungarian 29-01-2024
Patient Information leaflet Patient Information leaflet Maltese 31-01-2024
Public Assessment Report Public Assessment Report Maltese 29-01-2024
Patient Information leaflet Patient Information leaflet Dutch 31-01-2024
Public Assessment Report Public Assessment Report Dutch 29-01-2024
Patient Information leaflet Patient Information leaflet Polish 31-01-2024
Public Assessment Report Public Assessment Report Polish 29-01-2024
Patient Information leaflet Patient Information leaflet Portuguese 31-01-2024
Summary of Product characteristics Summary of Product characteristics Portuguese 31-01-2024
Public Assessment Report Public Assessment Report Portuguese 29-01-2024
Patient Information leaflet Patient Information leaflet Romanian 31-01-2024
Public Assessment Report Public Assessment Report Romanian 29-01-2024
Patient Information leaflet Patient Information leaflet Slovak 31-01-2024
Public Assessment Report Public Assessment Report Slovak 29-01-2024
Patient Information leaflet Patient Information leaflet Slovenian 31-01-2024
Summary of Product characteristics Summary of Product characteristics Slovenian 31-01-2024
Public Assessment Report Public Assessment Report Slovenian 29-01-2024
Patient Information leaflet Patient Information leaflet Finnish 31-01-2024
Public Assessment Report Public Assessment Report Finnish 29-01-2024
Patient Information leaflet Patient Information leaflet Swedish 31-01-2024
Public Assessment Report Public Assessment Report Swedish 29-01-2024
Patient Information leaflet Patient Information leaflet Norwegian 31-01-2024
Summary of Product characteristics Summary of Product characteristics Norwegian 31-01-2024
Public Assessment Report Public Assessment Report Norwegian 29-01-2024
Patient Information leaflet Patient Information leaflet Icelandic 31-01-2024
Summary of Product characteristics Summary of Product characteristics Icelandic 31-01-2024
Public Assessment Report Public Assessment Report Icelandic 29-01-2024
Patient Information leaflet Patient Information leaflet Croatian 31-01-2024
Public Assessment Report Public Assessment Report Croatian 29-01-2024

Search alerts related to this product

View documents history